Growth continued in Q2, profitability better but more to be achieved
31/07/20 -"AstraZeneca reported a healthy Q2 growth, outperforming closer peers like Novartis and Roche. This healthy performance was largely driven by oncology (c.45% of group sales). Moreover, the group is a ..."
Pages
64
Language
English
Published on
31/07/20
You may also be interested by these reports :
21/11/25
Ever since Sandoz demerged from Novartis, the generics/biosimilars giant has been delivering on its promises, and remains well on track to achieve ...
19/11/25
AstraZeneca has been beating the street’s estimates over the last few quarters, on the back of strong growth momentum for its oncology, rare disease, ...
18/11/25
Over past eighteen months, there has been a glaring performance divergence for family-owned Ipsen (BUY; France) vs. AV Small Pharmas. While the ...
17/11/25
Our 2025 estimates have been revised significantly, following a substantial guidance upgrade during Q3 results, driven by stronger-than-expected ...